These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19245906)

  • 1. The influence of (18)flourodeoxyglucose positron emission tomography on the management of gastroesophageal junction carcinoma.
    Smith JW; Moreira J; Abood G; Aranha GV; Nagda S; Wagner RH; Shoup M
    Am J Surg; 2009 Mar; 197(3):308-12. PubMed ID: 19245906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
    Swisher SG; Erasmus J; Maish M; Correa AM; Macapinlac H; Ajani JA; Cox JD; Komaki RR; Hong D; Lee HK; Putnam JB; Rice DC; Smythe WR; Thai L; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Cancer; 2004 Oct; 101(8):1776-85. PubMed ID: 15386332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.
    Konski AA; Cheng JD; Goldberg M; Li T; Maurer A; Yu JQ; Haluszka O; Scott W; Meropol NJ; Cohen SJ; Freedman G; Weiner LM
    Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):358-63. PubMed ID: 17532577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Fluorodeoxyglucose-positron emission tomography in carcinoma of the esophagogastric junction].
    Wang T; Sun YE; Chu XY; Tian JH; Liu Y
    Zhonghua Wai Ke Za Zhi; 2004 Jun; 42(11):651-3. PubMed ID: 15329251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma.
    Hong D; Lunagomez S; Kim EE; Lee JH; Bresalier RS; Swisher SG; Wu TT; Morris J; Liao Z; Komaki R; Ajani JA
    Cancer; 2005 Oct; 104(8):1620-6. PubMed ID: 16118804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of maximum standardized uptake values from preoperative positron emission tomography in resectable adenocarcinoma of the esophagus treated by surgery alone.
    Shenfine J; Barbour AP; Wong D; Thomas J; Martin I; Gotley DC; Smithers BM
    Dis Esophagus; 2009; 22(8):668-75. PubMed ID: 19222534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a role for PET/CT with esophagogastric junction adenocarcinoma?
    Fuster D; Mayoral M; Rubello D; Pineda E; Fernández-Esparrach G; Pagès M; Colletti PM; Pons F
    Clin Nucl Med; 2015 Mar; 40(3):e201-7. PubMed ID: 25546207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
    Lordick F; Ott K; Krause BJ; Weber WA; Becker K; Stein HJ; Lorenzen S; Schuster T; Wieder H; Herrmann K; Bredenkamp R; Höfler H; Fink U; Peschel C; Schwaiger M; Siewert JR
    Lancet Oncol; 2007 Sep; 8(9):797-805. PubMed ID: 17693134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma.
    Javeri H; Xiao L; Rohren E; Lee JH; Liao Z; Hofstetter W; Maru D; Bhutani MS; Swisher SG; Macapinlac H; Wang X; Ajani JA
    Cancer; 2009 Nov; 115(22):5184-92. PubMed ID: 19685531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer.
    Vallböhmer D; Hölscher AH; Schneider PM; Schmidt M; Dietlein M; Bollschweiler E; Baldus S; Alakus H; Brabender J; Metzger R; Mönig SP
    J Surg Oncol; 2010 Aug; 102(2):135-40. PubMed ID: 20648583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
    Levine EA; Farmer MR; Clark P; Mishra G; Ho C; Geisinger KR; Melin SA; Lovato J; Oaks T; Blackstock AW
    Ann Surg; 2006 Apr; 243(4):472-8. PubMed ID: 16552197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative EOX treatment in operable locally advanced gastroesophageal adenocarcinoma: Prediction of tumor response by FDG -PET and histopathology.
    Vihervaara H; Ålgars A; Kemppainen J; Sundström J; Ristamäki R; Salminen P
    Surg Oncol; 2019 Mar; 28():42-49. PubMed ID: 30851910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorine-18 fluorodeoxyglucose positron emission tomography in the preoperative staging of thoracic oesophageal and gastro-oesophageal junction cancer: a prospective study.
    Katsoulis IE; Wong WL; Mattheou AK; Damani N; Chambers J; Livingstone JI
    Int J Surg; 2007 Dec; 5(6):399-403. PubMed ID: 17631431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction.
    Wieder HA; Ott K; Lordick F; Becker K; Stahl A; Herrmann K; Fink U; Siewert JR; Schwaiger M; Weber WA
    Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1925-32. PubMed ID: 17680242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of pre-therapeutic FDG-PET radiomic analysis in gastro-esophageal junction cancer.
    Amrane K; Thuillier P; Bourhis D; Le Meur C; Quere C; Leclere JC; Ferec M; Jestin-Le Tallec V; Doucet L; Alemany P; Salaun PY; Metges JP; Schick U; Abgral R
    Sci Rep; 2023 Apr; 13(1):5789. PubMed ID: 37031233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus.
    Smithers BM; Couper GC; Thomas JM; Wong D; Gotley DC; Martin I; Harvey JA; Thomson DB; Walpole ET; Watts N; Burmeister BH
    Dis Esophagus; 2008; 21(2):151-8. PubMed ID: 18269651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic response evaluation by PET during neoadjuvant treatment for adenocarcinoma of the esophagus and esophagogastric junction.
    Sendler A
    Recent Results Cancer Res; 2010; 182():167-77. PubMed ID: 20676880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in preoperative staging of gastric adenocarcinoma with positron emission tomography.
    Chen J; Cheong JH; Yun MJ; Kim J; Lim JS; Hyung WJ; Noh SH
    Cancer; 2005 Jun; 103(11):2383-90. PubMed ID: 15856477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.